Latest Articles

Publication Date
Pulmonary alveolar proteinosis diagnosed during leuprorelin acetate therapy for ovarian endometrioma: a case report.

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder characterized by impaired surfactant clearance due to alveolar macrophage dysfunction. Leuprorelin acetate, a gonadotropin-releasing hormone agonist, is widely used in the …

Published: July 17, 2026, midnight
Vitamin D3 promotes regression of endometrial implants comparable to buserelin in a rat model of endometriosis.

Buserelin, a gonadotropin-releasing hormone agonist, reduces gonadotropin and estrogen levels and is commonly used to alleviate the symptoms of endometriosis. Vitamin D3 has been reported to exhibit anti-inflammatory and pro-apoptotic …

Published: June 30, 2026, midnight
Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review.

Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen …

Published: June 25, 2026, midnight
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.

To review recent evidence on the association between progestin exposure and meningioma risk and to propose practical recommendations for hormonal management in women requiring progestin therapy.

Published: June 21, 2026, midnight
Preliminary Evaluation of Leuprorelin Acetate Microspheres Plus Levonorgestrel-Releasing Intrauterine System in Endometriosis: An Exploratory Study Focusing on BNIP3 and EPAC1 Expression.

This exploratory pilot study aimed to assess the preliminary clinical effects of leuprorelin acetate microspheres for injection [gonadotropin-releasing hormone agonist (GnRH-a)] combined with levonorgestrel-releasing intrauterine system (LNG-IUS) in treating endometriosis …

Published: May 14, 2026, midnight
Terazosin as a Non-Hormonal Treatment for Endometriosis.

Endometriosis is a chronic, estrogen-dependent inflammatory disease including aberrant local steroidogenesis, inflammation, angiogenesis, oxidative stress, and prostaglandin-mediated pain. Given the elevated adrenergic receptor expression in endometriotic lesions and the potential …

Published: May 2, 2026, midnight
Electrospun Cellulose Acetate Nanofibers for Healthcare Products: Towards Sensing Pads for Endometriosis.

The need for reliable preventive medicine tools is growing, especially for diseases with long diagnostic delays, such as endometriosis, which can take several years to diagnose. In this context, cellulose …

Published: April 24, 2026, midnight
Contraceptive-Induced Weight Gain-Myth and Reality Review.

The perception that hormonal contraception causes weight gain is a general belief that frequently hinders the initiation and continuation of effective family planning. This narrative review analyses data from Cochrane …

Published: March 27, 2026, midnight
ASPIRIN ENHANCES ENDOMETRIAL DECIDUALIZATION MARKERS IN VITRO AMONG WOMEN WITH AND WITHOUT ENDOMETRIOSIS.

Decidualization of human endometrial stromal cells (ESCs) precedes the successful implantation of a human embryo. Improper decidualization has been reported in numerous conditions associated with infertility including endometriosis. Multiple pathways, …

Published: March 10, 2026, midnight
Metformin sensitizes endometriosis to medroxyprogesterone acetate treatment through MIG-6 mediated signaling.

This study evaluates the synergistic therapeutic effect of metformin (MET) combined with medroxyprogesterone acetate (MPA) on endometriosis (EM) and investigates the involvement of the steroid receptor coactivator-1 (SRC-1) and mitogen-inducible …

Published: March 6, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!